TENX Tenax Therapeutics Inc.

Tenax Therapeutics, Inc. engages in the identification, development, and commercialization of novel therapeutic products for the critical care market. Its lead product candidate is Levosimendan, a calcium sensitizer activator for intravenous use in hospitalized patients with acutely decompensated heart failure. The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.

Company profile

Ticker

TENX

Exchange

NASDAQ

Website

www.tenaxthera.com

CEO

Anthony A. DiTonno

Incorporated

Delaware

Location

North Carolina

Fiscal year end

Dec 31

Sector

Health Technology > Medical Specialties

Industry (SIC)

Services - Commercial Physical & Biological Research

PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Syneos Health • Medpace • Incyte • Exelixis • Icon • Precigen ...

Former names

OXYGEN BIOTHERAPEUTICS, INC., SYNTHETIC BLOOD INTERNATIONAL INC, SINEQUANON CORP

SEC CIK

0000034956

Corporate docs

Articles of Incorporation & Bylaws

IRS number

262593535

TENX stock data

S&P 500

1M 1Y 2Y 5Y

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

15 May 20

8 Aug 20

31 Dec 20

News

Company financial data Financial data

Chart TENX financial data

Quarter (USD)	Mar 20	Dec 19	Sep 19	Jun 19
Revenue
Net income	2.65M	-14M	2.22M	1.76M
Diluted EPS	-0.38	-0.42	-0.33	-0.28
Operating income	2.67M	-14.3M	2.26M	1.82M
Net change in cash	-1.04M	-1.25M	-1.76M	-1.91M
Cash on hand	4.36M	5.4M	6.65M	8.41M
Cost of revenue

Annual (USD)	Dec 19	Dec 18	Dec 17	Dec 16
Revenue				0
Net income	-8.39M	-14.14M	-8.84M	-43.92M
Diluted EPS	-1.35	-9.04	-6.27	-31.24
Operating income	-8.56M	-6.89M	-9.21M	-52.65M
Net change in cash	-7.5M	3.4M	-12.4M	-16.3M
Cash on hand	5.4M	12.9M	9.5M	21.9M
Cost of revenue				0

Financial data from company earnings reports

Recent insider trades

TENX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	10b5-1	$Price	#Shares	$Value	#Remaining
18 May 20	Blanck Ronald R	Common Stock	Buy	Aquire P	No	0	5,000	0	6,062
1 May 20	Proehl Gerald T	Stock Option Common Stock	Grant	Aquire A	No	0.66	500	330	500
1 May 20	Mitchum James P.	Stock Option Common Stock	Grant	Aquire A	No	0.66	500	330	500

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2020

TENX institutional ownership history Ownership history

12.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	21	21	–
Opened positions	4	3	+33.3%
Closed positions	4	5	-20.0%
Increased positions	2	2	–
Reduced positions	4	2	+100.0%

13F shares	Current	Prev Q	Change
Total value	876K	1.75M	-49.9%
Total shares	1.53M	1.24M	+23.7%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
BLK BlackRock	599.1K	$342K	0.0%
Renaissance Technologies	580.45K	$332K	+29.5%
Armistice Capital	181.15K	$104K	NEW
Financial Advisory Service	58.58K	$33K	0.0%
BK Bank of New York Mellon	35.14K	$20K	-1.2%
Geode Capital Management	33.02K	$18K	-0.1%
Sabby Management	32.84K	$19K	-23.9%
Vanguard	12.2K	$7K	0.0%
UBS UBS	1.49K	$1K	+1966.7%
Skandinaviska Enskilda Banken AB	140	$0	0.0%

Largest transactions	Shares	Bought/sold	Change
Armistice Capital	181.15K	+181.15K	NEW
Renaissance Technologies	580.45K	+132.11K	+29.5%
Sabby Management	32.84K	-10.32K	-23.9%
LTSF Ladenburg Thalmann Financial Services	0	-5.02K	EXIT
Advisor	0	-3.07K	EXIT
DB Deutsche Bank	0	-1.54K	EXIT
UBS UBS	1.49K	+1.42K	+1966.7%
BK Bank of New York Mellon	35.14K	-432	-1.2%
BAC Bank of America	100	+100	NEW
Advisor	65	+65	NEW

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Cytokinetics

Content analysis ?

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absence, acquisition, administered, Aid, alternative, ambulatory, annum, appeal, atrial, attendance, Award, bankruptcy, baseline, belief, bid, cardiac, certify, chain, chronic, civil, clarity, collateral, compliance, comply, concurrent, confidence, controversy, coverage, criminal, cure, damage, decline, deducting, default, deferred, delist, delisted, delisting, Department, disbursed, discouraging, disruption, dosing, economy, eligibility, employed, employee, encouraging, endpoint, epidemic, exceed, exposure, fail, faith, False, federal, fewer, forgiven, found, frequent, geography, good, government, governmental, harm, health, hearing, heightened, HFpEF, HFrEF, Hg, Horizon, impede, inaccurate, industry, ineligible, infected, institutional, interrupt, interruption, Lender, listed, listing, loan, lose, matter, media, minimize, minimum, mm, Monthly, movement, Nasdaq, negatively, notice, notification, outbreak, output, pandemic, panel, Paycheck, payroll, placebo, placement, population, PPP, precautionary, predict, preemption, preliminary, prepay, primary, promissory, prorated, pump, qualification, randomization, randomized, receipt, regain, regimen, release, released, Relief, remotely, rendered, repay, reputation, responder, retain, risk, satisfied, satisfy, SBA, shorter, simplify, situation, Small, spread, sum, suspending, temporarily, thereunder, tolled, track, tribunal, typically, unblinded, underwriter, unregistered, violation, weekly, worldwide, written

Removed: activated, adjusted, aggregate, amortization, ASU, carryforward, cease, CEO, conform, constitute, daily, director, dollar, earlier, enable, enrolling, February, forward, fourth, Gaining, headcount, historic, leased, leasing, longer, opening, package, policy, possession, practical, ratchet, Recent, reclassified, record, recruiting, require, retroactively, salary, split, targeted, transition, understand, volume

From filing 10-Q 2020 Q1